Indication
|
NAG, 2019
|
Stanford Antibiotics Guideline , 2019
|
Uptodate
|
|
Varicella zoster (Chicken Pox)
|
Immuno-
compromised
|
IV : 10mg/kg/dose q8h for 7 days (change to oral once there is an
improvement)
Advisable to start treatment early within 48 hours
|
IV : 10-12mg/kg/dose (500mg/M2)q8h
for 7 days
|
Severe or complicated infection
IV : 10 mg/kg/dose q8h for 7 -10 days ; some experts
recommend up to 15 mg/kg/dose q8h
May switch to oral antiviral after defervescence if no
evidence of visceral involvement; continue until all lesions have crusted
Uncomplicated infection
Oral: 800 mg 5x/day for 5 - 7 days; some experts recommend
a minimum duration of 7 days, extending the course until all lesions have
crusted
Initiate within 24 hours of symptom onset, may start later if patient still has active
lesion
|
Immuno-
competent
|
PO : 800mg 5x/day for 7 days
Advisable to start treatment early within 48 hours
|
PO : 800mg 5x/day for 5-7 days
Initiate within 24 hours of rash
|
PO: 800 mg 5x/day for ≥5 - 7 days
and until all lesions have crusted
Initiate within 24 hours of symptom onset, may start later
if patient still has active lesion
|
|
Herpes zoster
(Shingles)
|
Immuno-
compromised
|
Refer varicella zoster treatment
Systemic antiviral treatment is recommended to all immunocompromised
patient or for immunocompetent patients with the following criteria.
1.
>50 years
2.
Have moderate or severe pain
3.
Have moderate or severe rash
4.
Have have non truncal involvement
Advisable to start treatment early within 48-72 hours
|
Antiviral is indicated for patient fulfilling any of this criteria.
1.
>50 years
2.
Moderate to severe rash or pain
3.
Involvement of face/eye
4.
Acute complication of infection
5.
Immunocompromised state
Mild - Moderate
PO: 800 mg 5x/day for 7 days
Severe (patient with ocular or neurologic or disseminated disease)
IV: 10 to 15 mg/kg/dose q8h 7-14 days
7 days duration is reasonable in immunocompromised patient
, some experts continue until crusting of all lesion.
Benefit of antiviral therapy in immunocompetent hosts
>72 hours of symptoms is less clear.
Treatment is recommended for immunocompromised patients at
any time with active infection.
|
Acute localized dermatomal
PO: 800 mg 5x/day for 7 - 10 days; consider longer duration
if lesions resolve slowly
Extensive cutaneous lesions or
visceral involvement
IV: 10 to 15 mg/kg/dose q8h
When formation of new lesions has ceased and signs/symptoms
of visceral infection are improving, switch to an oral antiviral to complete
a total of 10 to 14 days of therapy
|
Immuno-
competent
|
PO: 800 mg 5x/day for 7 days
Initiate at earliest sign or symptom; treatment is most
effective when initiated ≤72 hours after
rash onset, but may initiate treatment >72 hours after rash onset if new
lesions are continuing to appear
|
|||
Viral Encephalitis
Herpes simplex
Varicella zoster
|
IV : 10mg/kg/dose q8h for 14-21 days
Consider using Ideal Body Weight for obese patient
|
IV : 10-12.5 mg/kg/dose q8h for
14-21 days
Dose calculation in obese patient
undertain
Higher doses up to 15mg/kg/dose q8h
have been used ion adults but with little additional benefit
|
IV: 10 mg/kg/dose q8h
Duration for encephalitis is 14 to 21 days and for
meningitis is 10 to 14 days
Treatment of
encephalitis requires IV therapy while treatment of meningitis may include
step-down oral antiviral therapy
|
|
Herpes simplex (Genital)
|
1) Initial Episode
A)
Immuno-
compromised
|
PO : 400mg q8h for 5 days
Only indicated within 5 days of start of new episode and
while new lesions are forming
|
PO: 400mg q8h for 7-10 days
For severe cases
IV : 5mg/kg/dose q8h for
5-7
days
|
Oral: 400 mg q8h for 5 - 10 days; extend
treatment duration if lesions have not healed completely after 10 days
For severe disease
IV : 5 to 10 mg/kg/dose q8h for 2 - 7 days, followed by oral acyclovir (or similar antiviral)
once lesions begin to regress and continue for ≥10 days of therapy and until complete resolution
|
b) Immuno-
competent
|
PO : 400 mg q8h or 200 mg 5x/day for 7 - 10 days; extend duration if lesions have not healed
completely after 10 days
For severe disease
IV : 5 to 10 mg/kg/dose q8h for 2 - 7 days, followed by oral acyclovir (or similar antiviral)
to complete ≥10 days of therapy total
|
|||
|
2) Recurrent
a ) Immuno-
compromised
|
Short course
PO : 800mg q8h for 2 days
5-days regimen
PO : 400mg q8h
Only indicated within 5 days of start of new episode and
while new lesions are forming
|
PO : 400mg q8h for 5-10 days
|
Oral: 400 mg q8h for 5 - 10 days; extend
treatment duration if lesions have not healed completely after 10 days
For severe disease
IV : 5 to 10 mg/kg/dose q8h for 2 - 7 days, followed by oral acyclovir (or similar antiviral)
once lesions begin to regress and continue for ≥10 days of therapy and until complete resolution
|
b) Immuno-
competent
|
PO : 800mg q8h x 2 days or
400mg q8h x 5
days
|
Oral: 400 mg q8h for 5 days or
800 mg q12h for 5 days or
800 mg q8h for 2 days
Treatment is most effective when initiated during the
prodrome or within 1 day of lesion onset
|
||
3) Supressive therapy
a)
Immuno-compromised
|
Indicated if ≥ 6 recurrences per
year, severe, prolonged or with psychosocial problems
PO : 400mg q12h
Duration up to 1 year then reassess
If breakthrough recurrences occur, dosage should be
increased , refer recurrent episode
|
PO : 400-800mg q8-12h
|
Indicated
for severe and/or frequent
recurrences
PO: 400 - 800 mg q8-12h
Reassess need periodically (eg, annually)
|
|
b)
Immuno-
competent
|
PO : 400mg q12h
|
Indicated
for severe and/or frequent
recurrences
PO: 400 mg q12h
Reassess need periodically (eg, annually)
|
||
4) Pregnancy (First episode)
|
PO : 400 mg q8h for 5 days
If during third trimester, continue
suppresive PO Acyclovir 400mg q8h until delivery
|
Not mentioned
|
PO : 400 mg q8h for 7 - 10 days; extend
treatment duration if lesion has not healed completely after 10 days
|
|
5) Pregnancy (
Recurrent)
|
Not mentioned
|
PO: 400 mg q8h or
800 mg q12h for 5 days
Some experts
reserve treatment of recurrent episodes for patients with severe and/or
frequent symptom
|
||
6) Pregnancy ( Suppressive
)
|
PO : 400 mg q8h
Treatment recommended starting at 36 weeks of gestation until delivery
|
PO: 400 mg q8h, beginning at 36 weeks' gestation and continued until the
onset of labor
Some experts offer suppressive therapy earlier than 36
weeks' gestation for women who have a first-episode lesion during the third
trimester
|
||
Herpes simplex (Mouth, lips: Oral lesion)
|
Symptomatic treatment in most cases
May consider
1.
Topical : Acyclovir 5% q4h
for 5-10 days in prodromal phase in recurrent herpes labialis
2.
Systemic antiviral : PO
400-800mg 5x/day for 7-14 days
|
PO : 400 mg 5x/day for (q4h while awake) x 5 days
Topical: Acyclovir 5% 6x/day (q3h) x 7 days
Start treatment with prodrome symptoms (tingling/burning) before
lesions appear
|
Topical : 1/2” ribbon of
ointment for a 4” square surface area q3h (6 times
daily) for 7 days
Treatment, initial or recurrent episode:
Oral: 400 mg q8h for 5 - 10 days and until complete lesion
resolution in immunocompromised patients
IV: 5 mg/kg/dose q8h for severe disease in
immunocompromised patients; switch to oral acyclovir (or similar antiviral)
once lesions begin to regress and continue until complete resolution
Suppressive therapy (eg, for
severe and/or frequent recurrences)
Oral: 400 mg q12h
Reassess need periodically (eg, annually)
|
|
Herpes simplex esophagitis
|
PO : 400mg q8h for 5 days
|
Not mentioned
|
Immunocompetent patients
PO : 400 mg q8h or
200 mg 5x/day for 7 to 10 days
Patients with severe odynophagia or dysphagia
IV: 5 mg/kg/dose q8h; patients who
rapidly improve can be switched to an oral antiviral to complete a total of 7
to 14 days of therapy
|
|
Herpes simplex keratitis
|
LA Acyclovir 3% 5x/day
In presence of stromal or
endothelial disease
PO: 400mg 5x/day for 7-14 days
Prophylaxis for recurrent
PO : 400mg q12h x 12 months
|
LA Acyclovir 3% 5x/day
PO: 400mg 5x/day for 7-14 days
Prophylaxis for recurrent
PO : 400mg q12h x 12 months
|
Topical : Apply a ½-inch ribbon of
ointment in the lower cul-de-sac of the affected eye(s) 5 times daily
(approximately every 3 hours while awake) until the corneal ulcer heals, then
apply a ½-inch ribbon 3 times daily for 7 days
PO: 400mg 5x/day
|
|
Herpes zoster ophtalmicus
|
Mild infection
PO : 400 mg q8h for 5 days
Severe life threatening
IV : 5-10mg/kg/dose q8h for 5 days or until to talke orally
|
Not mentioned
|
Immunocompromised patients or patients who require
hospitalization for sight-threatening disease
IV: 10 mg/kg/dose q8h for 7 days
|
|
Acute Retinal Necrosis
|
IV : 10mg/kg/dose q8h for 10-14 days
Followed by
PO: 800mg 5x/day for 6 weeks
|
IV : 10-12mg/kg q8h for 7-10 days until disease
stabilize then oral therapy for a minimum 6 weeks with valacyclovir or
famciclovir
|
IV: 10 - 15 mg/kg/dose q8h for 10 to 14 days, followed by ~6 weeks of valacyclovir
in HIV-infected patients, intravitreal ganciclovir should
be added
|
|
Viral pneumonia
|
IV : Acyclovir 10mg/kg/dose q8h x 7
days
|
Not mentioned
|
Not mentioned
|
Compiled by N. Nabiha [ 02 May 2020 ]
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.